SC amivantamab, in combination with LAZCLUZE, is recommended for adult patients with advanced NSCLC with epidermal growth ...

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

The increased understanding of the EGFR pathway in NSCLC with the identification of activating mutations in the tyrosine kinase domain of EGFR and the impressive clinical results observed with ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an ...

DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...

The Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-of-care Tagrisso in non-small cell lung cancer ...

Halozyme (HALO) announced that Janssen-Cilag International, a Johnson & Johnson (JNJ) company, received a positive opinion from the ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

EU regulators have issued a positive opinion for the extension of the market authorization for subcutaneous formulation of ...

Johnson & Johnson JNJ announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...